Yangbing Li
University of Michigan
27 Papers
68 Citations
Yangbing Li is an academic researcher from University of Michigan. The author has contributed to research in topics: Medicine & Catalysis. The author has an hindex of 9, co-authored 20 publications. Previous affiliations of Yangbing Li include Peking University.
Chat about Author
Papers
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Yangbing Li,Jiuling Yang,Angelo Aguilar,Donna McEachern,Sally Przybranowski,Liu Liu,Chao Yie Yang,Mi Wang,Xin Han,Shaomeng Wang +9 more
TL;DR: The design, synthesis, and evaluation of small-molecule MDM2 degraders based on the proteolysis targeting chimera (PROTAC) concept result in the most promising compound (MD-224), which achieves complete and durable tumor regression in vivo in the RS4;11 xenograft tumor model in mice at well-tolerated dose schedules.
248
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
TL;DR: This study provides the first example that simple structural modifications can convert a bona fide PROTAC degrader into a molecular glue compound, which has a completely different mechanism of action.
139
Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts.
Liu Liu,Ienglam Lei,Hacer Karatas,Yangbing Li,Li Wang,Leonid Gnatovskiy,Yali Dou,Shaomeng Wang,Li Qian,Zhong Wang +9 more
TL;DR: The studies show that targeting Mll1 dependent H3K4 methyltransferase activity provides specificity in the process of cardiac reprogramming, and shed new light on the molecular mechanisms underlying cardiac conversion of fibroblasts.
Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming
Yijing Guo,Yijing Guo,Ienglam Lei,Ienglam Lei,Shuo Tian,Wenbin Gao,Wenbin Gao,Karatas Hacer,Yangbing Li,Shaomeng Wang,Liu Liu,Zhong Wang +11 more
TL;DR: A combination of four chemicals, named here IMAP, suppresses specific C-C chemokine signaling pathways and facilitates Mef2c/Gata4/Tbx5 (MGT)-induced cardiac reprogramming, providing a potential means for iCM formation in clinical applications.
25
FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma.
Michael I. Barbato,Jeannette Nashed,Diana Bradford,Sachia Khasar,Banu S Zolnik,Hong-da Zhao,Yangbing Li,Youwei Bi,Stacy S. Shord,Anup K Amatya,Pallavi S. Mishra-Kalyani,Barbara Scepura,R. A. Al-Matari,Richard Pazdur,Paul G. Kluetz,Martha Donoghue,Harpreet Singh,Nicole L. Drezner +17 more
TL;DR: The most common (> 20%) adverse reactions were pyrexia, rash, headache, vomiting, musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage, abdominal pain and dermatitis acneiform.
24